利伐沙班的治疗效果

It is a new oral anticoagulant drug used for adult patients with non-valvular atrial fibrillation (excluding atrial fibrillation caused by rheumatic heart valve disease and atrial fibrillation after heart valve replacement) to reduce the risk of stroke and systemic embolism. What is the therapeutic effect of rivaroxaban?

To explore the effect of limb injury combined with rivaroxaban in preventing deep vein thrombosis after intertrochanteric fracture surgery and its impact on coagulation function indicators.

Methods 130 patients with postoperative intertrochanteric fracture were randomly divided into 2 groups. 65 patients in the control group were treated with rivaroxaban tablets, and 65 patients in the observation group were additionally treated with limb injury tablets for 4 weeks.

The rates of deep vein thrombosis and occurrence of adverse reactions in the two groups were counted, and the changes in thigh circumference difference, calf circumference difference, whole blood high-shear viscosity, whole blood low-shear viscosity, plasma viscosity, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) levels before and after treatment were observed.

Results The incidence of deep vein thrombosis in the observation group was significantly lower than that in the control group (P0.05); after treatment, the thigh circumference difference, calf circumference difference, whole blood high-shear viscosity, whole blood low-shear viscosity, plasma viscosity, platelet count and FIB level were significantly reduced (Pall <0.05), PT and APTT were significantly prolonged (Pall <0.05), and the improvement of the above indicators in the observation group was significantly better than that of the control group (Pall <0.05).

Conclusion: Limshang Yifang combined with rivaroxaban tablets can effectively prevent postoperative deep vein thrombosis in patients with intertrochanteric fractures, eliminate limb edema, improve hemorrheology and coagulation indicators, and is safe.

The recommended dose is: 10 mg orally, once daily. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.